The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Red blood cell–derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy
Open accessAbstract
We developed an antigen delivery system based on the nanoerythrocyte vehicle combined with anti–PD-L1 for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Jonuleit, H., Kühn, U., Müller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J., & Enk, A. H. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271209 · Cited by 1,163
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,056
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Self-citationPROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization
Dehaini, D., Wei, X., Fang, R. H., Masson, S., Angsantikul, P., Luk, B. T., Zhang, Y., Ying, M., Jiang, Y., Kroll, A. V., et al. (2017) · Advanced Materials · doi:10.1002/adma.201606209 · Cited by 769
Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells
Luft, T., Pang, K. C., Thomas, E., Hertzog, P., Hart, D. N. J., Trapani, J., & Cebon, J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1947 · Cited by 611
Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
Self-citationGao, M., Liang, C., Song, X., Chen, Q., Jin, Q., Wang, C., & Liu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201701429 · Cited by 590
Self-citationHost expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96113 · Cited by 584
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524
Biomaterial-assisted targeted modulation of immune cells in cancer treatment
Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 467
IFN-γ production by antigen-presenting cells: mechanisms emerge
Frucht, D. M., Fukao, T., Bogdan, C., Schindler, H., O'Shea, J. J., & Koyasu, S. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02005-1 · Cited by 461
A facile approach to enhance antigen response for personalized cancer vaccination
Li, A. W., Sobral, M. C., Badrinath, S., Choi, Y., Graveline, A., Stafford, A. G., Weaver, J. C., Dellacherie, M. O., Shih, T.-Y., Ali, O. A., et al. (2018) · Nature Materials · doi:10.1038/s41563-018-0028-2 · Cited by 390
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Tang, J., Yu, J. X., Hubbard-Lucey, V. M., Neftelinov, S. T., Hodge, J. P., & Lin, Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.210 · Cited by 382
Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells
Cheung, A. S., Zhang, D. K. Y., Koshy, S. T., & Mooney, D. J. (2018) · Nature Biotechnology · doi:10.1038/nbt.4047 · Cited by 372
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Park, C. G., Hartl, C. A., Schmid, D., Carmona, E. M., Kim, H.-J., & Goldberg, M. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar1916 · Cited by 321
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
Self-citationCombination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 271
Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination
Xia, Y., Wu, J., Wei, W., Du, Y., Wan, T., Ma, X., An, W., Guo, A., Miao, C., Yue, H., et al. (2018) · Nature Materials · doi:10.1038/nmat5057 · Cited by 268
Chiang, C. L.-L., Benencia, F., & Coukos, G. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.02.004 · Cited by 247
Wilson, D. S., Hirosue, S., Raczy, M. M., Bonilla-Ramirez, L., Jeanbart, L., Wang, R., Kwissa, M., Franetich, J.-F., Broggi, M. A. S., Diaceri, G., et al. (2019) · Nature Materials · doi:10.1038/s41563-018-0256-5 · Cited by 222
Red Blood Cells as Smart Delivery Systems
Han, X., Wang, C., & Liu, Z. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00758 · Cited by 206
Self-citationBanchereau, J., & Palucka, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.149 · Cited by 154
Ing, R., Segura, M., Thawani, N., Tam, M., & Stevenson, M. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.441 · Cited by 133
Clinical cancer vaccine trials
Jäger, E., Jäger, D., & Knuth, A. K. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00318-7 · Cited by 131
Red Blood Cells for Drug Delivery
Yan, J., Yu, J., Wang, C., & Gu, Z. (2017) · Small Methods · doi:10.1002/smtd.201700270 · Cited by 93
Self-citationLejeune, A., Moorjani, M., Gicquaud, C., et al. (1994) · PubMed · Cited by 68
Banz, A., Cremel, M., Rembert, A., & Godfrin, Y. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.02.013 · Cited by 65
Structural elucidation of cell membrane-derived nanoparticles using molecular probes
Fan, Z., Zhou, H., Li, P. Y., Speer, J. E., & Cheng, H. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb00980k · Cited by 63
Zhou, L., YANG, K. Y., Dunaway, S., ABDEL‐MALEK, Z. A., Andl, T., Kadekaro, A. L., & Zhang, Y. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12657 · Cited by 12
Cited by
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy
Zhang, C., Zeng, Z., Cui, D., He, S., Jiang, Y., Li, J., Huang, J., & Pu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23194-w · Cited by 411
Tailoring Materials for Modulation of Macrophage Fate
Li, J., Jiang, X., Li, H., Gelinsky, M., & Gu, Z. (2021) · Advanced Materials · doi:10.1002/adma.202004172 · Cited by 403
Self-citationMa, W., Yang, Y., Zhu, J., Jia, W., Zhang, T., Liu, Z., Chen, X., & Lin, Y. (2022) · Advanced Materials · doi:10.1002/adma.202109609 · Cited by 300
Self-citation
Metadata
- Authors
- Han, X., Shen, S., Fan, Q., Chen, G., Archibong, E., Dotti, G., Liu, Z., Gu, Z., & Wang, C.
- Venue
- Science Advances
- Published
- 2019-10-11
- Volume
- 5
- Issue
- 10
- Pages
- eaaw6870-eaaw6870
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W2982245165
- Cited by
- 349
- References
- 42
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.